If you are planning a US launch for a capsule skincare line, expect the paperwork to start early. The Modernization of Cosmetics Regulation Act, signed in December 2022, was the largest expansion of FDA authority over cosmetics since 1938. It replaced decades of voluntary practice with mandatory facility registration, product listing, safety substantiation, and adverse event reporting, for foreign and domestic manufacturers alike.
The statute is not complicated. What trips brands up is the division of labour: which duty belongs to the brand, which to the factory, and which documents must exist before a shipment can clear. For a soft-capsule product that answer is more favourable than for most formats.
At CapsulesBiotech we manufacture single-dose soft capsules for facial serum oils, eye serums, hair oils, body lotions, creams, and masks, using either a 100% plant-based shell or a food-grade gelatin shell. Much of our current work is for brands preparing US entries.
The Obligations That Actually BiteIn plain English, MoCRA asks a brand entering the US to do five things:
- Register each manufacturing facility through Cosmetics Direct; foreign facilities must name a US Agent
- List every marketed product with an INCI ingredient list within 120 days of first marketing, refreshed annually
- Name a Responsible Person: the manufacturer, packer, or distributor whose name appears on the label
- Hold adequate safety substantiation for each product, available to FDA on request; a safety-not-determined warning no longer substitutes
- Report serious adverse events within 15 business days, keeping records for six years
A small-business exemption from registration and listing exists, but it is narrower than it sounds: it does not cover safety substantiation or adverse event reporting.
Where Capsule Brands Get StuckThe role that causes the most confusion is the Responsible Person: a brand that commissions product under its own label is typically the Responsible Person, even though the factory does the manufacturing. The listing, the safety file, and the adverse event clock sit with the brand; the evidence behind them is generated on the factory floor. Unresolved, both sides assume the other holds the documents.
What a Factory Can Hand YouWe are a contract manufacturer, not your regulatory counsel, but we can put much of the technical file in your hands:
- Full ingredient declarations with INCI names for the finished fill
- Formulation and filling specifications, including fill weight tolerances
- Stability and compatibility data for your chosen shell, carrier, and actives
- Batch records, plus the registration details your listing needs
- Documentation a qualified toxicologist can work from when assembling the safety file
A sealed single-dose capsule is a comparatively simple regulatory object. Because the fill is protected from air and light and used once, the formula needs no preservative system, which removes preservative-efficacy testing from your documentation. Microbial risk is contained by a closed unit, dose is fixed by fill weight, and the opaque shell shields light-sensitive oils across the shelf life. None of that exempts a product from MoCRA; it means fewer moving parts when you assemble the file.
If you are preparing a US launch, the useful first step is a short brief rather than a finished formula. Tell CapsulesBiotech your target market, your positioning, and the sensory profile you have in mind, and we will come back with a formula direction, the filling specification, and a production schedule, so you can weigh the capsule format against a real timeline.